Core Viewpoint - The National Healthcare Security Administration (NHSA) announced the 2025 version of the National Basic Medical Insurance Drug List and the first Commercial Health Insurance Innovative Drug List, which includes significant updates to enhance drug accessibility for patients [1][2][3]. Group 1: Drug List Adjustments - The new drug list adds 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are either unavailable or can be replaced by others [1][2][3]. - The total number of drugs in the list now stands at 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with improved coverage for critical areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1][2][3]. Group 2: Financial Implications - The NHSA has assessed the budget impact of new drugs on the medical insurance fund, concluding that the overall financial burden remains manageable within the national budget [3][4][12]. - The introduction of new drugs may lead to increased costs, but many are expected to replace older medications, mitigating the financial impact [3][4][12]. Group 3: Challenges in Hospital Implementation - Despite being included in the insurance list, many "nationally negotiated drugs" face challenges in being adopted by hospitals due to limited capacity in hospital drug lists, which typically accommodate only 1,500 to 2,000 drugs [4][6][8]. - The approval process for new drugs in hospitals can be lengthy, often taking from one to twelve months, which complicates timely access for patients [8][12][44]. Group 4: Dual-Channel Policy - To address the issue of drug availability, the government introduced a "dual-channel" policy, allowing patients to access "nationally negotiated drugs" through designated hospitals and retail pharmacies, ensuring equal reimbursement [14][16][50]. - As of now, 402 nationally negotiated drugs have been integrated into this dual-channel system, significantly increasing sales from under 4 billion yuan in 2020 to nearly 15 billion yuan in 2024 [16][50]. Group 5: Commercial Health Insurance Innovations - The newly established Commercial Health Insurance Innovative Drug List includes 19 drugs, selected from 121 candidates, aimed at covering high-value drugs not included in the basic insurance [27][30][67]. - This list is designed to complement the basic medical insurance system, addressing the gap for high-cost innovative treatments that are crucial for patients with severe conditions [30][32][67]. Group 6: Future Implications - The introduction of the Commercial Health Insurance Innovative Drug List is expected to enhance patient access to high-value treatments, encouraging insurance companies to cover these drugs and potentially increasing patient enrollment in commercial health plans [30][66][73]. - The dual-directory approach aims to create a more robust healthcare financing system, ensuring that patients can access necessary medications while maintaining the sustainability of the insurance funds [30][66][73].

Core Viewpoint - The article discusses the recent update of China's National Medical Insurance Drug List, which includes 114 new drugs, highlighting the introduction of a commercial health insurance innovative drug directory alongside the basic insurance list, aiming to enhance patient access to innovative treatments and address gaps in drug coverage [6][13]. Group 1: New Drugs in the National Medical Insurance Directory - A total of 114 new drugs have been added to the directory, covering various treatment areas including 36 for tumors, 12 for chronic diseases, and 10 for rare diseases, with the number of class 1 new drugs increasing from 38 to 50, setting a new historical high [6][7]. - Notable "star drugs" include LuKangsa Tazhu (for tumors), Fluorazirase tablets, and Spilumab (for specific dermatitis), which will benefit a wide range of patients, including those with triple-negative breast cancer and chronic sinusitis [7][8]. Group 2: Financial Impact on Patients - The average price reduction for negotiated drugs has historically been around 60%, with 112 out of 127 drugs successfully negotiated this year, resulting in significant cost savings for patients [9]. - The introduction of Spilumab, priced at around 1,000 yuan per injection, is expected to significantly lower the financial burden on patients, making innovative treatments more accessible [9]. Group 3: Implementation Challenges - There are concerns regarding the "last mile" issue in drug availability at hospitals, as many negotiated drugs are still provided through external pharmacies, and hospitals may hesitate to prescribe these due to cost concerns [10][11]. - The new regulations require that hospitals must not limit the availability of negotiated drugs based on overall budget constraints, ensuring that these drugs are accessible to patients [11]. Group 4: Changes in the Drug Directory - This year, 29 drugs were removed from the directory due to being replaced or not produced, with a total of 467 drugs removed over the past eight years for similar reasons [12]. - A six-month transition period has been established for patients using drugs that are not renewed in the directory, ensuring continuity of care [12]. Group 5: Commercial Health Insurance Innovative Drug Directory - The newly established commercial health insurance innovative drug directory includes 19 drugs, focusing on high-value innovative treatments that cannot be covered by the basic insurance directory [13][15]. - The drugs in this directory are characterized by high innovation, significant clinical value, and the need for diverse payment options, with 50% being class 1 new drugs [15]. Group 6: Benefits for Patients - The commercial health insurance directory aims to provide a curated list of high-quality drugs, reducing the selection burden for insurance companies and potentially lowering costs for patients through reduced premiums or increased reimbursement rates [16]. - The integration of the commercial insurance directory with existing medical insurance systems is being explored to enhance patient experience and access to innovative treatments [16]. Group 7: Future Prospects and Challenges - The implementation of the commercial health insurance innovative drug directory is dependent on market mechanisms, with insurance companies determining the usage and timing of these drugs [19]. - Emphasis on actuarial pricing and collaboration between insurance companies and pharmaceutical firms is crucial for the sustainable rollout of these innovative drugs [19].

Core Insights - The National Healthcare Security Administration (NHSA) announced the 2025 version of the National Basic Medical Insurance Drug List, which includes 114 new drugs, 50 of which are innovative drugs, while 29 drugs were removed due to lack of supply or better alternatives [1][2][4] Group 1: Drug List Adjustments - The total number of drugs in the directory has increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines, significantly enhancing coverage for critical areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1][4] - The new directory will be implemented nationwide starting January 1, 2026 [1] Group 2: Innovative Drug Access Challenges - Despite the inclusion of innovative drugs in the directory, there are challenges in getting these drugs into hospitals due to limited capacity in hospital drug lists, which typically accommodate only 1,500 to 2,000 drugs [6][9] - Hospitals face difficulties in deciding whether to replace existing drugs with newly added "nationally negotiated drugs," leading to a cautious approach in procurement [7][11] Group 3: Financial Implications for Healthcare Providers - The NHSA has assessed the budget impact of new drugs on the healthcare fund, indicating that the overall financial burden will remain manageable within the national healthcare budget [5] - Hospitals are under pressure to control costs, especially as high-priced innovative drugs could lead to reduced budget surpluses or even deficits [13][15] Group 4: Dual-Channel Policy for Drug Distribution - The "dual-channel" policy allows patients to access "nationally negotiated drugs" through designated hospitals and retail pharmacies, ensuring equal reimbursement rates [16][18] - This policy has successfully increased the availability of critical drugs, with sales of "nationally negotiated drugs" rising from under 4 billion yuan in 2020 to nearly 15 billion yuan in 2024 [21] Group 5: Commercial Health Insurance Innovations - The NHSA introduced the first Commercial Health Insurance Innovative Drug List, which includes 19 drugs, to complement the basic medical insurance system and address the coverage gap for high-value innovative drugs [31][34] - This new list aims to facilitate better access to expensive treatments that are not covered by basic insurance, thereby reducing the financial burden on patients [40][42]

Group 1 - The core viewpoint of the articles is that regulatory reforms in Beijing are significantly enhancing the pharmaceutical and healthcare industry, aiming for a market value exceeding one trillion yuan through various supportive policies [1][2][3]. Group 2 - The approval time for clinical trials of innovative drugs has been reduced from 60 days to 30 days, with some projects being approved in as little as 18 working days [2][3]. - A total of 26 drug varieties have been approved, including 21 for rare diseases, benefiting approximately 4,900 patients [2]. - The Beijing model includes measures such as bonded stockpiling and multiple uses of a single customs clearance to expedite access to urgently needed drugs [2][3]. Group 3 - The overall time for initiating clinical trial projects is targeted to be reduced from 28 weeks to under 20 weeks by 2024, with some hospitals already achieving a reduction to around 7 weeks [3][4]. - A green channel has been established for innovative drugs, allowing for simultaneous reviews of project initiation, ethical review, and contract review, significantly shortening approval times [4]. Group 4 - The National Medical Insurance Bureau has implemented a dynamic adjustment mechanism for the medical insurance catalog, adding 835 new drugs over seven years, including 149 innovative drugs [5]. - Approximately 80% of innovative drugs are expected to be included in the medical insurance catalog within two years of their market launch [5][6]. - In the first seven months of 2025, 13.05 million patients purchased national negotiated drugs, totaling 3.95 billion yuan in expenses [5]. Group 5 - A dual-channel supply mechanism for national negotiated drugs has been established to ensure accessibility and address issues related to slow and difficult hospital entry [5][6]. - The Beijing Medical Insurance Fund will separately pay 4.5 billion yuan for national negotiated drugs in 2024, ensuring that these drugs are not subject to DRG payment limits [6][7]. Group 6 - The establishment of a drug and medical device review center in the Beijing-Tianjin-Hebei region aims to accelerate the approval process for innovative drugs and medical devices [8]. - The center will provide comprehensive technical services, including guidance and consultation for drug and device registration, focusing on clinical needs [8].

Core Viewpoint - The story highlights the journey of a child with spinal muscular atrophy (SMA) and the impact of national healthcare policies on access to life-saving treatments, showcasing the importance of medical advancements and insurance negotiations in improving patient outcomes [1][14]. Group 1: Medical Condition and Treatment - The child, known as Little Stone, was diagnosed with SMA at eight months old, with initial medical advice suggesting a grim prognosis and no available treatments in China [3][5]. - A special drug, Nusinersen, was introduced in China in early 2019, but its high cost of approximately 700,000 yuan per injection posed a significant financial burden for the family [5][10]. - In 2020, the drug's price was reduced to 550,000 yuan per injection, and the company offered a buy-one-get-five-free deal, improving the child's condition through ongoing rehabilitation and treatment [8][12]. Group 2: Healthcare Policy and Insurance Negotiations - The first round of national healthcare negotiations in 2021 saw the drug's price drop dramatically from 550,000 yuan to around 30,000 yuan, making it accessible for more patients [10][12]. - The negotiations aimed to balance the interests of patients, pharmaceutical companies, and the healthcare fund, reflecting a significant shift in the availability of rare disease treatments in China [10][14]. - Following the successful negotiations, the number of patients using Nusinersen in 2022 increased significantly, with a reported 2.6 times growth in sales compared to the previous year [12]. Group 3: Social Integration and Support - Little Stone successfully enrolled in elementary school, with the institution making special accommodations to support his learning needs, demonstrating a positive societal response to children with disabilities [16][18]. - The family continues to face challenges, including ongoing rehabilitation sessions and the aging of family members who provide support [20]. - The narrative emphasizes the importance of community support, family involvement, and healthcare policies in enabling children with rare diseases to integrate into society and pursue education [21].

创新医药支付渠道不断拓展。据介绍，北京及时将符合条件的创新药品纳入北京普惠健康保特药清单， 2025年度特药清单共有106种特药，其中国内特药41种，海外特药65种。此外，积极推动医疗健康数据 赋能创新。建成国内首个人工智能领域监管沙盒机制，发布全国首个场景化、字段级数据出境负面清 单，建立数据出境"绿色通道"服务机制，其中，拜耳公司项目整体用时29个工作日。在投融资支持方 面，不断加强创新医药企业投融资支持，充分发挥市级200亿元医药健康投资基金的作用，坚持投早投 小投长期，2024年投决金额和撬动社会资本近100亿元。 北京市医保局表示，《若干措施》为北京市创新药和创新医疗器械高质量发展提供关键动力和战略抓 手，激发创新医药企业整体活力。缩短产品从研发到上市应用的全链条创新周期，推动医药制造数智化 转型；丰富人工智能应用场景，赋能创新医药发展；优化创新医药产业布局，加强知识产权保护，推动 本市生物医药产业和金融保险业协同发展，打造支撑医药健康产业高质量发展的多层次人才梯队，不断 满足人民群众日益增长的健康需求。 北京商报记者 王寅浩 4月7日，北京市医保局等九部门发布《北京市支持创新医药高质量发展若干措施 ...